Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on March 31, 2023. The filing serves to announce the company's financial results for the fourth quarter and the full fiscal year ended December 31, 2022. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Alameda, California.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release furnished as Exhibit 99.1, which is not included in the provided text. Consequently, no specific financial figures can be extracted from this document alone.
Material Changes
The filing does not provide specific data regarding material changes versus prior periods. It solely indicates that the results for the fourth quarter and fiscal year 2022 have been announced via a press release.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words such as "may," "will," "believes," or "expects" are forward-looking and subject to risks and uncertainties.
- Risk Factors: The company directs investors to its periodic reports filed with the SEC under the heading "Risk Factors" for additional details on factors that could cause actual results to differ materially from anticipated results.
- Outlook: No specific guidance or management commentary regarding future performance is included in the text of this 8-K.
Important Facts for Investor Verification
- Verify the specific financial results (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated March 31, 2023), as this 8-K only references the announcement.
- Confirm the company name is AgeX Therapeutics, Inc. (Ticker: AGE), noting the discrepancy with the "Serina Therapeutics" name in the request metadata.
- Review the company's most recent 10-K or 10-Q filings for detailed "Risk Factors" and historical financial data to contextualize the Q4 2022 results.
- Note that the information in Item 2.02 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.